Cytodyn Inc (CYDY)

[ClosetInvestor]

Remember, this “great” data is the same data that NP sent to 1,000 BPs 6 months ago. I’d assume BP would’ve jumped on this quickly 6 if a big partnership or buyout was warranted.

https://www.businesswire.com/news/home/20220105005661/en/Leronlimab-14-Week-NASH-Clinical-Trial-Met-Primary-Endpoint-PDFF-and-Secondary-Endpoint-cT1-for-Per-Protocol-Population-in-350-mg-Weekly-Dose

Also recall that a CCR5 inhibitor, cenicriviroc, failed a large NASH trial earlier this year. That was a costly failure as the trail needed to enroll 1778 patients, required biopsies and followed the patients up to 42 months.

https://clinicaltrials.gov/ct2/show/NCT03028740

Cenicriviroc’s failure doesn’t equate to a pending leronlimab NASH failure, but partners may be hesitant to throw large sums of money at the trial as we’ve seen in the previous years